Moderate-to-Severe Asthma Management

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Asthma Introduction

The Unmet Medical Needs of Asthma

Asthma Is a Heterogeneous Disease

Case: Stephanie

Achieving Control in Asthma

Assessing Asthma Control

Assessing Future Risk

The Goal of Asthma Management

Triggers and Comorbidities

Adherence and Persistence to Asthma Medication

Shared Decision Making in Asthma Management

GINA-Based Steps for Asthma Treatment

Case: Stephanie – 10 Months Later

Defining "Severe Asthma"

Pathobiology of Asthma

Pathobiology of Asthma

Emerging Asthma Phenotypes

Asthma Biomarkers

Current and Emerging Targeted Therapies for Severe Asthma

Omalizumab: an Anti-IgE Agent

Anti-IL-5 Therapy in Eosinophilic Asthma

Anti-IL-5 Therapy in Eosinophilic Asthma

Investigational Agents for Severe Asthma

Take-Home Points

Abbreviations

Abbreviations (cont)